Table 1.
Characteristics of tumours (n = 22) with an immunohistochemistry outcome
| Characteristics | n (%) |
|---|---|
| Age at diagnosis (years)a,b | 60 ± 12 |
| Histological subtype | |
| Invasive ductal carcinoma (IDC) | 14 (64) |
| Invasive lobular carcinoma (ILC) | 4 (18) |
| Mixedc | 2 (9) |
| Invasive mucinous carcinoma (IMC) | 2 (9) |
| Nuclear grade | |
| 1 | 3 (14) |
| 2 | 10 (45) |
| 3 | 9 (41) |
| Molecular subtype | |
| ER + /HER2 − | 17 (77) |
| ER + /HER2 + | 5 (23) |
| Carcinoma in situ | |
| Absence | 4 (18) |
| Presence | 18 (82) |
| Necrosis | |
| Absence | 19 (86) |
| Presence | 3 (14) |
| Nodal (N) statusa | |
| Negative | 12 (60) |
| Positive | 8 (40) |
| Pathological tumour size (mm)d | 22 [10–63] |
| Tumour longest diameter on MRI (mm)d,e | 25.6 [10–60] |
| Tumour volume (cm3)d,f | 2.19 [0.29–21.17] |
| Enhancing tumour volume (cm3)d,f | 1.85 [0.29–12.95] |
aCalculated in n = 20 patients
bData presented as mean ± standard deviation (SD)
cCancers with the presence of both ductal and lobular components
dData presented as median [range]
ePathological tumour size was defined as the largest tumour diameter measured on surgical specimens
fCalculated in n = 20 cancers, for which both DCE-MRI and immunohistochemistry data were available
ER + , oestrogen receptor–positive; HER2 − , human epidermal growth factor 2-negative; HER2 + , human epidermal growth factor 2-positive